The University of Hong Kong

Runming Wang

Hongzhe Sun

Hongyan Li

Tsz Pui Lai

Hongmin Zhang

Richard Yi Tsun Kao

Qi Zhang

Shing Chow Chan

Chi-Fung Godfrey Chan

Pak Leung Ho

Chi Fung Godfrey Chan

Shing Chan

Disclosed are pharmaceutical compositions containing (a) polymyxin antibiotic and (b) a mobile colistin resistant proteins (MCRs) inhibitor. The inhibitor relates to silver/gold-compounds or the pharmaceutically acceptable salts thereof. Also disclosed are methods of making silver/gold-compounds or the pharmaceutically acceptable salts thereof and methods for treating MCR-producing bacterial infection via multiple mechanisms.

Silver-/gold-compounds and methods thereof

The present disclosure relates to methods of using cisplatin active agents in which reduced organ toxicity is observed are provided. In the subject methods, an effective amount is administrated to the host before administration of an effective amount of cisplatin active agents. The cisplatin toxicity reducing agent comprising of stable bismuth(III) complexes or pharmaceutically acceptable salts reduces the levels of undesired toxicity of cisplatin active agents without compromising their anticancer activity. Also provided are methods for use in practicing the subject methods in the treatment of different disease conditions.

Bismuth(III) complexes as adjuvants in the treatment of cancer using platinum-based chemotherapy

The present disclosure relates to a pharmaceutical composition comprising: (a) &#x3b2;-lactam antibiotics and (b) a metallo-&#x3b2;-lactamases (MBLs) inhibitor. The inhibitor relates to Bi(III) compounds or the pharmaceutically acceptable salts thereof. The present patent also provides methods of making Bi(III) compounds or the pharmaceutically acceptable salts thereof. Also provided is a method for treating MBLs-producing bacterial infection using a metal replacement mechanism.

Bismuth(III) compounds and methods thereof

Growing community of inventors

Hong Kong, China

Runming Wang